Article
Hospital-based surveillance and analysis of genotype variation in Nicaragua after the introduction of the pentavalent rotavirus vaccine.
The Pediatric infectious disease journal - 1 Jan 2014
Khawaja Shazia, Cardellino Anna, Mast T Christopher
Abstract excerpt
BACKGROUND: A live, attenuated, pentavalent rotavirus vaccine (RV5) was introduced in Nicaragua in 2006 through a 3-year partnership between Merck & Co, Inc., and the Nicaraguan Ministry of Health. Nicaragua was the first developing nation to include rotavirus vaccine in its national childhood vaccine program. To monitor the possibility of changing circulating rotavirus strains after the introduction of RV5, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
